You are here: Home » 2025 » March » Archives for 17th

Curia Anuncia Expansão da Rede Global de Locais de Processamento Final Estéril

ALBANY, N.Y., March 17, 2025 (GLOBE NEWSWIRE) — A Curia Global, Inc. (Curia), uma organização líder em contratos de pesquisa, desenvolvimento e fabricação, anunciou hoje planos de expansão de suas instalações em Glasgow, Reino Unido, e forneceu atualizações sobre a expansão em andamento em Albuquerque, NM.

A instalação de processamento final estéril da Curia em Glasgow adicionará uma linha de processamento final de frascos integrada e baseada em isolador e um liofilizador adequado para uma ampla gama de medicamentos, incluindo recursos altamente potentes, mais do que dobrando o tamanho atual do lote de GMP. Já conhecida por seus conjugados anticorpo–droga (ADCs), nanopartículas lipídicas (LNPs), desenvolvimento de liofilização, formulação e desenvolvimento complexos, e experiência de fabricação clínica, a expansão em Glasgow fortalecerá ainda mais a oferta da Curia de desenvolvimento de produtos injetáveis estéreis desde a pré–formulação, passando pelas fases clínicas e de fabricação comercial.

Além de aumentar o tamanho dos lotes em até 20.000 frascos, a nova capacidade contará com tecnologia de processamento final robótica e sem perdas situada dentro de um isolador para permitir velocidades de processamento final cinco vezes mais rápidas do que as capacidades atuais. O liofilizador adicional também fornecerá aos clientes em estágio clínico mais escalabilidade no caminho para a comercialização e criará uma oportunidade para futuros processamentos finais comerciais de pequeno volume em Glasgow. A instalação continuará atendendo clientes com operações normais durante a expansão.

“Nosso investimento em Glasgow ressalta o compromisso da Curia de ser um parceiro completo”, disse Philip Macnabb, CEO da Curia. “Existe muita inovação nos estágios iniciais do desenvolvimento clínico, e a Curia está pronta para atender à crescente demanda de maior capacidade para nossos clientes em estágio clínico.”

A expansão de Glasgow se soma a um investimento de US $ 200 milhões em um projeto de expansão plurianual em andamento nas instalações da Curia em Albuquerque. Duas linhas de processamento final isoladas adicionarão mais de 70.000 pés quadrados ao espaço de fabricação de mais de 200.000 pés quadrados de Albuquerque e criarão uma capacidade clínica e comercial significativa de fase III para seus clientes. Uma Linha VarioSys™ Flex, adequada para produtos biológicos de pequena escala e pequenas moléculas não potentes, pode acomodar seringas, cartuchos e frascos. Esta linha está passando por comissionamento. Além disso, a nova linha de frascos de alta velocidade da Curia começará a ser comissionada no terceiro trimestre de 2025. A nova linha de frascos de alta velocidade inclui dois liofilizadores automáticos, inspeção automatizada de frascos e rotulagem/embalagem para frascos de 2R a 30R.

“O aumento da demanda por agonistas de GLP–1, novos medicamentos biológicos, juntamente com as avaliações contínuas da cadeia de suprimentos por nossos clientes, tornam este o momento ideal para que essa capacidade em Albuquerque seja disponibilizada”, disse Macnabb. “A Curia é ideal para ajudar nossos clientes a enfrentar todos esses desafios com nossas várias instalações de fabricação nos EUA, experiência na cadeia de suprimentos e capacidade prontamente disponível.”

A rede global de instalações de processamento final estéril da Curia também inclui capacidades de desenvolvimento clínico e fabricação em Camarillo e Thousand Oaks, CA e capacidades de fabricação comercial e clínica em Burlington, MA.

Sobre a Curia
A Curia é uma Organização de Desenvolvimento e Fabricação por Contratos (CDMO) com mais de 30 anos de experiência, uma rede integrada de mais de 20 locais em todo o mundo e 3.100 funcionários em parcerias com clientes biofarmacêuticos para lançamento no mercado terapias que mudam a vida. Nossas ofertas de pequenas moléculas, APIs genéricos e produtos biológicos resultam em descobertas através da comercialização, com integridade regulatória, de capacidade analítica e processamento final estéril. Nossos especialistas científicos e de processos, juntamente com nossas instalações em conformidade regulatórias, oferecem a melhor experiência em fabricação de medicamentos e produtos farmacêuticos. Da curiosidade à cura, proporcionamos todas as etapas necessárias para acelerar sua pesquisa e melhorar a vida dos pacientes. Visite–nos em curiaglobal.com.

Contato Corporativo:
Viana Bhagan
Curia
+1 518 512 2111
[email protected]


GLOBENEWSWIRE (Distribution ID 9394930)

Curia kündigt Erweiterung des globalen Netzwerks steriler Abfüllanlagen an

ALBANY, N.Y., March 17, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), ein führendes Unternehmen für Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen, gab heute Expansionspläne für seinen Standort in Glasgow, Großbritannien, bekannt und informierte über den aktuellen Stand der laufenden Expansion in Albuquerque, New Mexico.

Die sterile Abfüllanlage von Curia in Glasgow wird um eine integrierte, isolatorbasierte Abfülllinie für Ampullen und einen Gefriertrockner erweitert, der für eine breite Palette von Arzneimitteln geeignet ist, einschließlich hochwirksamer Produkte, wodurch die derzeitige GMP–Chargengröße mehr als verdoppelt wird. Curia ist bereits für seine Antikörper–Wirkstoff–Konjugate (ADCs), Lipidnanopartikel (LNPs), die Entwicklung von Gefriertrocknung, komplexe Formulierungen und Entwicklung sowie seine Erfahrung in der klinischen Fertigung bekannt. Durch die Erweiterung in Glasgow wird das Angebot von Curia im Bereich der Entwicklung steriler injizierbarer Produkte von der Vorformulierung über die klinischen Phasen bis hin zur kommerziellen Fertigung weiter gestärkt.

Zusätzlich zur Erhöhung der Chargengröße auf bis zu 20.000 Phiolen wird die neue Anlage mit einer robotergestützten, verlustfreien Abfülltechnologie ausgestattet sein, die sich in einem Isolator befindet und Abfüllgeschwindigkeiten ermöglicht, die fünfmal schneller sind als die derzeitigen Möglichkeiten. Der zusätzliche Gefriertrockner bietet Kunden im klinischen Stadium auch mehr Skalierbarkeit auf dem Weg zur Vermarktung und schafft die Möglichkeit für zukünftige kommerzielle Abfüllungen in kleinen Mengen in Glasgow. Die Einrichtung wird während der Erweiterung Kunden wie gehabt bedienen.

„Unsere Investition in Glasgow unterstreicht das Engagement von Curia, ein umfassender Partner zu sein“, so Philip Macnabb, CEO von Curia. „In den frühen Phasen der klinischen Entwicklung gibt es so viel Innovation, und Curia ist bestrebt, die wachsende Nachfrage nach mehr Kapazität für unsere Kunden in der klinischen Phase zu decken.“

Die Erweiterung in Glasgow erfolgt zusätzlich zu einer Investition von 200 Millionen US–Dollar in ein laufendes, mehrjähriges Erweiterungsprojekt in der Curia–Einrichtung in Albuquerque. Zwei isolierte Abfüllanlagen werden die über 200.000 Quadratmeter große Produktionsfläche von Albuquerque um über 70.000 Quadratmeter erweitern und eine bedeutende klinische und kommerzielle Phase–III–Kapazität für seine Kunden schaffen. Eine VarioSysTM Flex–Anlage, die für kleine Mengen an Biologika und nicht potenten kleinen Molekülen geeignet ist, kann Spritzen, Kartuschen und Phiolen aufnehmen. Diese Anlage wird derzeit in Betrieb genommen. Darüber hinaus wird die neue Hochgeschwindigkeits–Phiolenanlage von Curia im 3. Quartal 2025 in Betrieb genommen. Die neue Hochgeschwindigkeits–Phiolenanlage umfasst zwei automatisch beladene Gefriertrockner, eine automatische Phioleninspektion und eine Etikettier–/Verpackungsanlage für 2R– bis 30R–Phiolen.

„Die erhöhte Nachfrage nach GLP–1–Agonisten und neuen biologischen Arzneimitteln in Verbindung mit den laufenden Überprüfungen der Lieferkette durch unsere Kunden machen dies zu einem idealen Zeitpunkt, um diese Kapazität in Albuquerque in Betrieb zu nehmen“, fuhr Macnabb fort. „Curia ist ideal aufgestellt, um unseren Kunden bei all diesen Herausforderungen mit unseren zahlreichen Produktionsstätten in den USA, unserer Expertise in der Lieferkette und unserer sofort verfügbaren Kapazität zu helfen.“

Das weltweite Netzwerk steriler Abfüllanlagen von Curia umfasst auch klinische Entwicklungs– und Fertigungskapazitäten in Camarillo und Thousand Oaks, Kalifornien, sowie kommerzielle und klinische Fertigungskapazitäten in Burlington, Massachusetts.

Über Curia
Curia ist ein Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen (CDMO) mit über 30 Jahren Erfahrung, einem integrierten Netzwerk von über 20 Standorten weltweit und 3.100 Mitarbeitern, die mit biopharmazeutischen Kunden zusammenarbeiten, um lebensverändernde Therapien auf den Markt zu bringen. Unser Angebot an niedermolekularen, generischen Wirkstoffen und Biologika reicht von der Entdeckung bis zur Vermarktung und umfasst integrierte regulatorische, analytische und sterile Abfüll– und Veredelungskapazitäten. Unsere wissenschaftlichen und technischen Experten bieten zusammen mit unseren regulatorisch konformen Einrichtungen erstklassige Erfahrung in der Herstellung von Arzneimitteln und Produkten. Von der Neugier bis zur Heilung – wir unterstützen Sie bei jedem Schritt, um Ihre Forschung zu beschleunigen und das Leben von Patienten zu verbessern. Besuchen Sie uns unter curiaglobal.com.

Firmenkontakt:
Viana Bhagan
Curia
+1 518 512 2111
[email protected]


GLOBENEWSWIRE (Distribution ID 9394930)

Curia Announces Expansions to Global Network of Sterile Fill-Finish Sites

ALBANY, N.Y., March 17, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced expansion plans to its Glasgow, UK facility and provided updates on the ongoing expansion in Albuquerque, NM.

Curia’s sterile fill–finish facility in Glasgow will add an integrated, isolator–based vial filling line and lyophilizer suitable for a broad range of drug product including highly potent capabilities, more than doubling current GMP batch size. Already known for its antibody drug conjugates (ADCs), lipid nanoparticles (LNPs), lyophilization development, complex formulation and development, and clinical manufacturing experience, the Glasgow expansion will further strengthen Curia’s offering of sterile injectable product development from pre–formulation, through the clinical phases and commercial manufacturing.

In addition to increasing batch sizes up to 20,000 vials, the new capacity will feature robotic, lossless filling technology situated within an isolator to allow filling speeds five times faster than current capabilities. The additional lyophilizer will also provide clinical–stage clients more scalability on the path to commercialization and creates an opportunity for future small–volume commercial fills in Glasgow. The facility will continue serving clients with normal operations during the expansion.

“Our investment in Glasgow underscores Curia’s commitment to being an end–to–end partner,” said Philip Macnabb, CEO of Curia. “So much innovation exists in the early stages of clinical development, and Curia is eager to meet the growing demand for increased capacity for our clinical–stage clients.”

The Glasgow expansion is in addition to a $200 million investment in an ongoing, multi–year expansion project at Curia’s Albuquerque facility. Two isolated filling lines will add over 70,000 square feet to Albuquerque’s over 200,000–square–foot manufacturing space and will create significant phase III clinical and commercial capacity for its clients. A VarioSysTM Flex Line, suitable for small–scale biologics and non–potent small molecules can accommodate syringes, cartridges and vials. This line is currently undergoing commissioning. Additionally, Curia’s new high–speed vial line will begin commissioning in Q3 2025. The new high–speed vial line includes two autoloaded freeze driers, automated vial inspection and labeling/packaging for 2R to 30R vials.

“Increased demand for GLP–1 agonists, new biologic drugs, coupled with on–going supply chain reviews by our customers make this an ideal time for this capacity In Albuquerque to come on–line,” Macnabb went on to say. “Curia is ideally suited to help our clients meet all of these challenges with our multiple U.S. manufacturing facilities, supply chain expertise and readily available capacity.”

Curia’s global network of sterile fill–finish facilities also includes clinical development and manufacturing capabilities in Camarillo and Thousand Oaks, CA and commercial and clinical manufacturing capabilities in Burlington, MA.

About Curia
Curia is a contract research, development and manufacturing organization (CDMO) with over 30 years of experience, an integrated network of 20+ global sites and 3,100 employees partnering with biopharmaceutical customers to bring life–changing therapies to market. Our offerings in small molecule, generic APIs and biologics span discovery through commercialization, with integrated regulatory, analytical and sterile fill–finish capabilities. Our scientific and process experts, along with our regulatory compliant facilities, provide a best–in–class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate your research and improve patients’ lives. Visit us at curiaglobal.com.

Corporate Contact:
Viana Bhagan
Curia
+1 518 512 2111
[email protected]


GLOBENEWSWIRE (Distribution ID 9394930)

BitMEX Announces a 345,000 USDT Prize Pool for New and Existing Traders to Win in March

MAHE, Seychelles, March 17, 2025 (GLOBE NEWSWIRE) — BitMEX, the OG crypto derivatives exchange, has announced a 345,000 USDT prize pool to celebrate the month of March.

The campaign, which began on 5 March, is available to new, existing, and returning traders on BitMEX. Key highlights of the campaign include:

  • Whale Wars Trading Competition: Users must aim for the highest trading volume, PnL, and/or ROI% to win their share of a 305,000 USDT prize pool
  • Spot Trading Arena: New users that trade BTC, ETH, SOL, XRP on BitMEX Spot will share a 40,000 USDT prize pool – with a guaranteed 100 USDT loss protection subsidy for BTC traders

The Whale Wars Trading Competition started on 5 Mar 2025 at 11:00 AM (UTC) and will end on 28 Mar 2025 at 11:59 PM (UTC). Traders can compete for the highest trading volume, PnL, and ROI%, with each trader eligible to win rewards across all three leaderboards.

Bottom traders will also stand to benefit, with a 2,500 USDT bonus available to the bottom 5 traders with the highest loss in PnL. For traders interested in participating in the competition, they can do so here.

The Spot Trading Arena will begin on 14 March 2025 at 12:00 AM (UTC) and will end on 31 March 2025 at 11:59 PM (UTC). Detailed information on the tasks and rewards can be found here.

To participate in BitMEX’s March campaign, new customers need to successfully sign up for a BitMEX account and complete their KYC process. For full details and registration, visit here.

About BitMEX

BitMEX is the OG crypto derivatives exchange, providing professional crypto traders with a platform that caters to their needs through low latency, deep crypto native liquidity and unmatched reliability.

Since its founding, no cryptocurrency has been lost through intrusion or hacking, allowing BitMEX users to trade safely in the knowledge that their funds are secure. So too that they have access to the products and tools they require to be profitable.

BitMEX was also one of the first exchanges to publish their on–chain Proof of Reserves and Proof of Liabilities data. The exchange continues to publish this data twice a week – proving assurance that they safely store and segregate the funds they are entrusted with.

For more information on BitMEX, please visit the BitMEX Blog or www.bitmex.com, and follow Telegram, Twitter, Discord, and its online communities. For further inquiries, please contact [email protected].


GLOBENEWSWIRE (Distribution ID 1001054131)

Zoom debuts new agentic AI skills and agents for Zoom AI Companion

  • Zoom AI Companion expands agentic skills across the entire Zoom platform, using reasoning and memory to take action and orchestrate task execution, conversational self–service, custom agent creation, and more
  • More than 45 new innovations announced, including AI enhancements for Zoom Meetings, Zoom Phone, Zoom Team Chat, Zoom Docs, and Zoom Contact Center, help users get more done, do their best work, and strengthen relationships
  • New Zoom customer experience (CX) innovations include next–generation enhancements to Zoom Virtual Agent chat and the introduction of Virtual Agent for voice, AI intent routing capabilities, and Advanced Quality Management

ORLANDO, Fla., March 17, 2025 (GLOBE NEWSWIRE) — Today Zoom Communications, Inc. (NASDAQ: ZM) unveiled agentic AI Companion capabilities, new Zoom AI Companion skills, and AI updates across its platform, including Zoom Meetings, Zoom Team Chat, Zoom Docs, Zoom Phone, Zoom Whiteboard, Zoom Contact Center, industry solutions, and more.

“AI Companion is evolving from a personal assistant to being truly agentic, which signals a major leap forward in how AI can enhance productivity and collaboration at work,” said Smita Hashim, chief product officer at Zoom. “We’re delivering value for our customers through AI agents and agentic skills that solve real customer problems, helping them connect, collaborate, and get more done, all within the Zoom platform our users trust and love.”

“We’ve been using Zoom AI Companion since it became available, and I’ve seen firsthand how it has transformed our academic and administrative operations,” said Steven Carroll, chief information officer at Saint Leo University. “This technology isn’t just about efficiency; it allows our employees to spend less time on manual tasks and more time on meaningful collaboration, and focus on what matters most: supporting our students’ educational journey.”

AI Companion takes action with AI skills and agents

Zoom is elevating AI Companion across its entire platform through AI agentic skills, agents, and models to deliver high–quality results, help users improve productivity, and strengthen relationships.

  • AI Companion will help users get more done by executing on their behalf and managing multi–step actions with the knowledge of which agents and skills to tap into using reasoning and memory to make decisions, solve complex problems, and learn over time, along with task action and orchestration to execute and complete tasks.
  • Additional new agentic skills include calendar management to help schedule meetings and find a time that works for everyone, clip generation for fast clip creation, writing assistance for advanced document creation, and more.
  • AI Companion will also extend to specialized agents that power Zoom Business Services. For customer self–service, Zoom Virtual Agent leverages memory and reasoning skills to deliver empathetic and contextual conversations and task action to resolve complex issues from start to finish. With AI Studio, users can effortlessly create and deploy customizable virtual agents (available in beta later this spring). Zoom Revenue Accelerator users will also be able to benefit from a specialized agent for sales in the coming months to help increase revenue through automated insights, personalized outreach and enhanced prospecting.
  • Coming soon, with Zoom’s open platform, users will be able to interact with third–party agents such as ServiceNow AI Agents and create their own custom agents with specific skill sets to address unique needs, such as streamlining sales RFPs or IT and HR service requests. AI Companion will know when to work with third–party and custom agents to take action and complete tasks.

Custom AI Companion add–on will allow organizations to customize AI Companion with AI Studio by tailoring it to address their unique needs and drive efficiency.

  • Organizations will be able to create custom meeting templates and custom dictionaries with vocabulary unique to their business or industry, incorporate information from their own data sources, including compatible third–party applications, and use AI Studio to expand AI Companion’s knowledge and skills to help drive decisions and actions and complete tasks.
  • Users will have access to a digital personal AI coach and custom meeting summary templates that will allow users to structure meeting summaries for specific industry verticals or use cases, such as one–on–one meetings, customer intake, or brainstorming meetings.
  • Users will also have access to Custom Avatars for Zoom Clips to help scale video clip creation and avoid multiple takes by using a personalized AI–generated avatar to create clips with a user–provided script. Custom Avatars will be included in the Custom AI Companion add–on and will also be available for purchase separately.
  • The Custom AI Companion add–on is expected to be available for purchase in April for $12 per user per month (personal coach is expected to be available in June).

As part of Zoom’s federated approach to AI, the Custom AI Companion add–on will incorporate Small Language Models (SLMs) alongside Zoom’s third–party LLMs to deliver industry–leading performance and cost–effectiveness for modern businesses. Zoom’s new SLMs are trained with extensive multilingual data, optimized for specific tasks to perform complex actions, and well–positioned to facilitate multi–agent collaboration.

Get more done with AI Companion

With new agentic skills, AI Companion can help users get more done, identify and execute tasks, manage meetings, and more. AI Companion’s agentic skills work across the platform to help reduce manual work so users can focus on what matters most.

  • Zoom Tasks with AI Companion will help users surface, complete, and manage tasks across Zoom Workplace by automatically detecting action items in meeting summaries, chats, and emails, and completing tasks like scheduling follow–up meetings or generating documents from meetings. Tasks will be available in a new tab within Zoom Workplace and can be embedded into a Zoom Doc, creating a central repository to track personal, team, and project tasks from creation to completion. Zoom Tasks is expected to launch at the end of March.
  • Meeting agendas with AI Companion, expected to launch in May, will help users stay organized by using templates or recent agendas to provide recommended content. Hosts will be able to add an agenda timer to sections to keep meetings on track and receive AI–generated live notes during the meeting. After the meeting, hosts will be able to easily share the summary and action items.
  • Live notes for Meetings and Phone, expected to launch in May, will provide real–time summaries during a meeting or phone call to help users catch up quickly, stay on track, focus on real–time topics connected to the agenda, and track updates live.
  • AI Companion for Zoom Phone can now generate voicemail summaries and support the Zoom for Microsoft Teams app. Zoom Phone calls within Microsoft Teams can generate AI Companion call summaries, and prioritize and extract tasks from voicemails.
  • A new voice recorder on the Zoom Workplace mobile app, expected to launch in late March, will transcribe, summarize, and capture action items with AI Companion and create high–quality recordings for in–person conversations, so users can connect without taking notes.
  • AI Companion for Workspace Reservation will show in–office workers when colleagues are expected to be in the office, recommend which days to go into the office based on scheduled meetings and their teammates’ scheduled in–office days, and have AI Companion proactively book a desk or a Zoom Room for them. These updates are expected to launch in May.

AI Companion helps users do their best work and get better results

Zoom Docs helps workers create high–quality content more efficiently by providing AI Companion writing assistance, as well as internal and external information search capabilities to help maximize productivity and streamline workflows.

  • Zoom Docs will have enhanced AI Companion capabilities with advanced references and queries that will be able to help a user create a writing plan based on the context, search internal and external information for references, and aggregate them into a high–quality business document based on user instructions. Advanced references and queries are expected to launch in June.
  • Users can prompt AI Companion to automatically create data tables, including from meeting summaries, so that content may be more easily digested and organized in a table format. AI Companion will be able to automatically label the columns so users can quickly see highlights and automate information like categorization and summarization for each record. This feature is expected to be available in July.

Zoom also announced Zoom Drive, a central repository for meeting and productivity assets such as Zoom Docs, that will make it easier to find and access assets across Zoom Workplace. Zoom Drive is expected to launch in May.

Zoom AI Companion continues to be included at no additional cost for customers with the paid services in their Zoom user accounts. Specialized AI Companion capabilities, custom agent configurations, and third–party agents may cost an additional fee or be subject to separate pricing.

Visit the Zoom newsroom for more information on Zoom’s approach to agentic AI and Zoom Workplace enhancements.

Strengthen relationships with Zoom Business Services

The Zoom Business Services suite for marketing, customer care, and sales includes AI–first solutions that are tightly integrated with Zoom Workplace and designed to help customer–facing employees strengthen customer relationships and improve customer experiences.

Zoom Customer Experience (CX)
Zoom is bringing agentic skills to Zoom Contact Center with specialized AI agents to help revolutionize customer experiences, empower customer service agents, and enhance self–service interactions while maintaining the importance of human connections.

  • New generative AI advancements with agentic AI skills will introduce the next evolution of self–service. Zoom Virtual Agent will offer more natural language skills, handle complex queries, and execute tasks on behalf of customers. To extend these capabilities, Zoom Virtual Agent will be available for voice and chat channels (planned for qualified customer beta later this spring), offering a seamless, always–on experience.
  • AI–intent routing (expected to launch at the end of March), will intelligently route customers to the best–suited agent based on real–time intent detection.
  • With Advanced Quality Management, contact center teams will have access to Auto Quality Management, which will use AI to automatically score up to 100% of customer interactions, and Ask Quality Management, which will deliver a conversational interface for supervisors to directly query transcripts and uncover valuable insights. Advanced Quality Management is expected to launch in May.

Visit the Zoom newsroom for an in–depth look at Zoom Business Services enhancements, including updates for Zoom Revenue Accelerator and Zoom Events.

Zoom delivers powerful industry–specific solutions

  • Zoom Workplace for Frontline, expected to launch in April, is a purpose–built, AI Companion–based, mobile solution that gives frontline workers the on–shift communications and work management tools needed to be more connected and efficient in their daily tasks.
  • Zoom Workplace for Clinicians, expected to launch at the end of March, is designed to streamline clinical workflows. It enables doctors, nurses, and practitioners to dedicate more time to patient care and engagement rather than spending valuable time on documentation and administrative tasks. Zoom Workplace for Clinicians will be able to automatically generate clinical notes in the office or a virtual Zoom telehealth appointment so that physicians can focus on what matters most: their patients.
  • Zoom Workplace for Education will provide AI Companion–generated lecture summaries with supporting material that teachers can use to generate assignments and students can use to create study materials (expected to be available in May). Later this year, a live notes feature will enable students to add comments, reactions, and highlights to the live transcripts to engage with lecture content during and post class to further learning.
  • The Zoom hardware certification program is expanding solutions to support industry verticals beginning in April:
    • For education customers, Zoom will add select document cameras, which are intended to capture documents or objects on a table that can be shared in a Zoom virtual meeting or class, to its certified hardware portfolio.
    • For healthcare customers, Zoom will certify select cameras for use in patient rooms, enabling remote observation of patients.

Some features and products may not be available for all regions and industry verticals.

About Zoom
Zoom’s mission is to provide an AI–first work platform for human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion that empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer experience teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

Zoom Public Relations
Lacretia Nichols
[email protected]


GLOBENEWSWIRE (Distribution ID 9395552)

Curia annonce l’extension de son réseau mondial de sites de remplissage et de finition stériles

ALBANY, État de New York, 17 mars 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), une organisation leader du domaine de la recherche, du développement et de la fabrication sous contrat, dévoile ce jour les projets d’agrandissement de son site de Glasgow, au Royaume–Uni, et fait le point sur le développement de celui d’Albuquerque, au Nouveau–Mexique.

Le site de remplissage et de finition stériles situé à Glasgow apporte à Curia une nouvelle ligne de remplissage de flacons intégrée à base d’isolateurs et un lyophilisateur adapté à une large gamme de produits pharmaceutiques, y compris des capacités de production extrêmement élevées, ce qui fera plus que doubler la taille des lots certifiés BPF actuels. Déjà connue pour ses conjugués anticorps–médicaments (ou ADC, pour antibody drug conjugates), ses nanoparticules lipidiques (ou LNP, de l’anglais lipid nanoparticles), son développement de la lyophilisation, sa formulation et son développement complexes, ainsi que pour son expérience en termes de fabrication clinique, l’unité de fabrication de Glasgow permettra, dans ses nouvelles dimensions, de consolider l’offre de Curia en matière de développement de produits injectables stériles, depuis la préformulation jusqu’à la fabrication commerciale, sans oublier les phases cliniques.

Outre l’augmentation de la taille des lots à concurrence de 20 000 flacons, la nouvelle usine sera dotée d’une technologie de remplissage robotisé sans perte située dans un isolateur pour atteindre des vitesses de remplissage cinq fois supérieures aux capacités actuelles. Le lyophilisateur supplémentaire permettra également aux clients en phase clinique de gagner en évolutivité sur la voie de la commercialisation et concrétise l’opportunité de proposer de futurs remplissages commerciaux de petits volumes à Glasgow. L’installation continuera à fonctionner normalement pendant les travaux d’agrandissement.

« Notre investissement à Glasgow vient souligner l’engagement de Curia en tant que partenaire de bout en bout », indique Philip Macnabb, PDG de la société. « Il existe une multitude d’innovations dans les premiers stades du développement clinique. Curia souhaite ardemment répondre à la demande croissante d’augmentation des capacités pour ses clients en phase clinique. »

L’agrandissement du site de Glasgow vient s’ajouter à un investissement de 200 millions de dollars visant un projet d’agrandissement pluriannuel en cours sur le site d’Albuquerque. Deux lignes de remplissage isolées viendront compléter l’espace de fabrication d’Albuquerque de plus de 70 000 pieds carrés (soit un peu plus de 6 500 mètres carrés), à noter que son périmètre actuel en représente plus de 200 000 (soit environ 18 580 mètres carrés). Elles permettront de mettre en place une importante capacité clinique et commerciale de phase III pour ses clients. Une ligne VarioSysTM Flex, adaptée aux produits biologiques de petite taille et aux petites molécules non puissantes, peut fabriquer des seringues, des cartouches et des flacons. La mise en service de cette ligne est actuellement en cours. Par ailleurs, la nouvelle ligne de flacons à grande vitesse de Curia démarrera au troisième trimestre 2025. La nouvelle ligne de flacons à grande vitesse comprend deux lyophilisateurs à chargement automatique, une inspection automatisée des flacons et un étiquetage/conditionnement de flacons de 2 à 30 ml.

« L’augmentation de la demande d’agonistes du GLP–1 et de nouveaux médicaments biologiques, associée à l’évaluation continue de la chaîne d’approvisionnement par nos clients, fait de cet instant l’occasion idéale pour mettre en service cette capacité sur le site d’Albuquerque », poursuit M. Macnabb. « À l’appui de ses multiples sites de production aux États–Unis, son expertise en matière de chaîne d’approvisionnement et sa capacité de production facilement disponible, Curia est parfaitement en mesure d’aider ses clients à relever tous ces enjeux. »

Le réseau mondial de sites de remplissage et de finition stériles de Curia comprend également des capacités de développement clinique et de fabrication à Camarillo et Thousand Oaks, dans l’État de Californie, ainsi que des unités de fabrication commerciale et clinique à Burlington, dans l’État du Massachusetts.

À propos de Curia
Curia est une organisation de recherche, de développement et de fabrication sous contrat (ou CDMO pour Contract Development and Manufacturing Organization) forte de plus de 30 ans d’expérience à son actif. Elle exploite un réseau intégré de plus de 20 sites à travers le monde et emploie quelque 3 100 collaborateurs travaillant en partenariat avec des clients biopharmaceutiques pour mettre sur le marché des traitements qui changent véritablement la vie des gens. Nos offres en matière de petites molécules, d’API génériques et de produits biologiques couvrent le cycle complet de la découverte à la commercialisation, et intègrent des capacités réglementaires, analytiques et de remplissage et finition stériles. Nos scientifiques, nos experts en processus et nos installations conformes aux réglementations en vigueur apportent une expérience de premier ordre dans la fabrication de substances et de produits pharmaceutiques. De la curiosité au traitement, nous réalisons toutes les étapes permettant d’accélérer vos recherches et d’améliorer la vie des patients. Consultez notre site à l’adresse curiaglobal.com.

Contact de l’entreprise :
Viana Bhagan
Curia
+1 518 512 2111
[email protected]


GLOBENEWSWIRE (Distribution ID 9394930)

The United States Confronts the Demographic Piper

The U.S. fertility rate has declined from nearly four births per woman in the early 1960s to a record low of approximately 1.6 births per woman today. Credit: Shutterstock

The U.S. fertility rate has declined from nearly four births per woman in the early 1960s to a record low of approximately 1.6 births per woman today. Credit: Shutterstock

By Joseph Chamie
PORTLAND, USA, Mar 17 2025 – As the United States confronts the unflinching demographic piper with the stark facts of reality, the new administration and Congress are denying, disengaging and dismantling.

Across virtually every demographic dimension, including population growth, fertility, mortality, morbidity, longevity, immigration, asylum, composition, ethnicity and ageing, the new US administration is repudiating, reframing and regressing on government policies, programs and commitments.

With respect to population growth, the United States is increasingly dependent on immigration. For the first time since 1850, when the US Census Bureau began compiling data on nativity, immigration accounted for the entire growth of the US population between 2022-23.

Furthermore, for the remainder of 21st century, immigration is expected to continue having significant consequences on the growth, composition and structure of the U.S. population.

The US Census Bureau’s main population projection assumes an annual net immigration level of nearly one million throughout the remainder of the 21st century. Accordingly, the US population is expected to reach 360 million by mid-century and peak at approximately 370 million by 2080 (Figure 1).

 

Source: US Census Bureau and author’s calculations.

 

Without future immigration, however, the U.S. population will begin to decline. If immigration to the country is stopped, the US population is projected to begin declining soon and fall below 300 million by 2060. Furthermore, the U.S. population without immigration is expected to decline to 226 million by the end of the century, which would be two-thirds its current population size.

If immigration to the country is stopped, the US population is projected to begin declining soon and fall below 300 million by 2060. Furthermore, the U.S. population without immigration is expected to decline to 226 million by the end of the century, which would be two-thirds its current population size

Also, about 20% of the country’s current labor force is foreign born with immigrant workers heavily involved in residential construction, agriculture, senior care and hospitality. Nevertheless, the administration seeks to modify US immigration laws and policies.

Among the administration’s modifications are policies and programs relating to expedited removal, self-deportation, mass deportation, unauthorized migrants, refugees, asylum seekers, temporary protected status, immigrant workers and legal immigrants.

Although the president ordered the shutdown of the US refugee program, a federal judge restored it temporarily while the lawsuit is pending with the program at a standstill and no refugees arriving in the country.

The composition of the U.S. population is also undergoing increasing diversity. The proportion of foreign-born living in the US, which was at a record low of about 5% in 1970, has reached a record high of 15.8% in 2025 with approximately 54 million foreign-born residents.

Moreover, while the U.S. non-Hispanic white population has been declining, the numbers of African Americans, Hispanics and Asian Americans have been increasing.

The ethnic composition of the foreign-born in the U.S. has also changed markedly over the recent past. Throughout the 19th and most of the 20th centuries, the US foreign-born population was predominantly from European countries, e.g., Germany, Ireland, Italy and the United Kingdom.

In 2022, the top five countries contributing to the U.S. foreign-born population were no longer of European origin. The countries of Europe have been replaced by Mexico, India, China, Philippines, and El Salvador, with Mexico accounting for nearly one quarter of the foreign-born in the United States.

Regarding U.S. fertility, the country’s rate has declined from nearly four births per woman in the early 1960s to a record low of approximately 1.6 births per woman today. With respect to expected future rates, the US Census Bureau and other organizations issuing population projections do not anticipate US fertility returning to the replacement level of about 2 births per woman any time soon.

Despite the fact that US fertility has fallen well below the replacement level, the president upon taking office issued an executive order restricting birthright citizenship.

The order declared that that citizenship would be denied to babies who do not have at least one parent who is a U.S. citizen or legal permanent resident. The president insists that the US Constitution’s 14th Amendment’s citizenship clause, specifically Section 1, does not apply to the births of unauthorized migrants.

The question of birthright citizenship has moved through the country’s courts with a nationwide pause imposed on the president’s executive order ending birthright citizenship for the children of unauthorized immigrants and foreign residents. The administration has pushed for the pause to be lifted by the US Supreme Court, which recently signaled it would consider the request to review the nationwide pause.

Turning to the important matter of infant, child and maternal mortality, the United States has the highest rates of any other high-income country. Furthermore, with a life expectancy at birth of about 78 years in 2022, the United States ranks around 50th in life expectancy among countries and about 30th among the 38 member states of the Organization for Economic Cooperation and Development (Table 1).

 

Source: United Nations and WHO.

 

To make America great again with respect to its comparatively high mortality levels is a significant undertaking. To do so would require increased political commitment, comprehensive medical and health programs and additional financial resources. And at this point in time, it appears highly unlikely that the administration will take those steps.

Furthermore, despite the fact that the country’s mortality rates and life expectancy lag behind other wealthy nations, the US president recently issued an executive order rolling back policies to limit drug spending by Medicaid and Medicare.

Also in its first weeks, the new administration announced far-reaching cuts in the Centers for Disease Control and Prevention. The government’s various actions have ground the National Institutes of Health (NIH) to a halt, set back its scientific reporting, censored terminology, disrupted communication activities about NIH grants and sent shockwaves through academia and the biomedical research institutions.

The new administration also imposed a new policy to cap indirect costs for NIH research grants at 15 percent. That policy change would cut billions of dollars in funding for life-saving research to develop cures and treatments for diseases.

At the Veteran Affairs agency, clinical trials have been delayed, contracts canceled and support staff fired. A much deeper round of cuts are being considered, including eliminating some 80,000 jobs and reviewing tens of thousands of contracts.

Recently, however, a federal judge ruled that federal agencies must immediately offer probationary workers purged by the new administration their jobs back. The judge found that the mass firings of employees from various government departments did not follow the law and the administration’s justification for the firings of works with probationary status was a sham. However, the administration has indicated that it would be appealing the court’s ruling.

Another judge ruled similarly saying that it was likely that the administration had engaged in an illegal scheme spanning broad swaths of the federal workforce and the administration was barred from carrying out future mass reductions.

The demographic ageing of the U.S. population has created economic concerns for the country. In 1960 about 9% of the U.S. population was aged 65 years or older. That proportion has nearly doubled to 17% today and is expected to reach close to 25% around mid-century.

With the noteworthy proportional increases in the population aged 65 years and older, the major entitlement programs, especially those aimed at the elderly, are consuming about half of all federal spending, i.e., 21% on Social Security and 28% on Medicare, Medicaid and other health care for fiscal year 2025 (Figure 2).

 

Source: US Treasury Department.

 

As the newly elected president and Republican Congressional leaders try to pass a tax cut extension to the Tax Cut and Jobs Act signed into law by the president in 2018, they are seriously considering possible cost reductions to the major entitlement programs, especially with respect to Medicaid and Children’s Health Insurance Program.

Additional proposals for reform and cutbacks are also being considered to reduce the rising cost of Social Security, which faces insolvency by 2033 if nothing is done by Congress. Among the various offered proposals to reduce costs are increasing the program’s age for receiving full retirement benefits, raising tax rates and the income limit earmarked for Social Security, and reducing the levels of benefits provided.

In sum, the United States is increasingly being confronted by the realities of the demographic piper. Despite those realities, the new administration and Republican Congressional leaders have decided to revise many of the country’s policies, eliminate or downsize programs, curtail scientific reporting, crackdown on dissent, decrease federal expenditures and reduce the federal workforce.

Unfortunately, the various changes, reductions, cutbacks, curtailments and fanciful promises made by the new administration do not address but only exacerbate the stark realities of the resolute demographic piper.

Joseph Chamie is a consulting demographer, a former director of the United Nations Population Division and author of numerous publications on population issues, including his recent book, “Population Levels, Trends, and Differentials”.

Bitdeer Launches SEALMINER A2 Pro Bitcoin Mining Machines

SINGAPORE, March 17, 2025 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR), a world–leading technology company for blockchain and high performance computing, today announced the launch of its latest self–developed Bitcoin mining machines, the SEALMINER A2 Pro series.

As the updated version of the SEALMINER A2, the A2 Pro series includes two models: the air–cooling SEALMINER A2 Pro Air and the hydro–cooling SEALMINER A2 Pro Hyd. Both deliver a record–breaking power efficiency ratio of 14.9 J/TH, offering higher efficiency ratios, advanced technologies, and enhanced stability.

Key specifications for both models:

  • SEALMINER A2 Pro Air: Power Efficiency Ratio of 14.9J/TH ±5%, Hashrate of 255TH/s to 270TH/s ±10%, Power Consumption of 3,790W to 4,050W ±10%.
  • SEALMINER A2 Pro Hyd: Power Efficiency Ratio of 14.9J/TH ±5%, Hashrate of 500TH/s to 530TH/s ±10%, Power Consumption of 7,450W to 7,900W ±10%.

The SEALMINER A2 Pro series marks a breakthrough in power supply efficiency, achieving up to 97%. The A2 Pro Hyd features enhanced high–temperature performance, operating efficiently with inlet water temperatures up to 60°C and outlet temperatures up to 70°C. Both models retain the series' signature low–noise design, minimizing operational noise disturbances.

Bitdeer remains committed to enhancing transparency and efficiency in the mining industry through research and development investments and technological innovations, providing the industry with efficient and reliable mining solutions. Bitdeer will continue to uphold the principles of “Innovation, Efficiency, and Stability”, offering global miners higher–quality and more reliable products and services.

About Bitdeer Technologies Group
Bitdeer is a world–leading technology company for blockchain and high–performance computing. Bitdeer is committed to providing comprehensive computing solutions for its customers. The Company handles complex processes involved in computing such as equipment procurement, transport logistics, datacenter design and construction, equipment management, and daily operations. The Company also offers advanced cloud capabilities to customers with high demand for artificial intelligence. Headquartered in Singapore, Bitdeer has deployed datacenters in the United States, Norway, and Bhutan.

About SEALMINER
SEALMINER, a pioneering brand of Bitcoin mining machines under Bitdeer Technologies Group (NASDAQ: BTDR), specializes in offering efficient and sustainable mining solutions. SEALMINER integrates Bitdeer's self–developed SEAL series of mining chips manufactured using advanced process nodes. By continuously improving power efficiency ratios, SEALMINER is dedicated to providing innovative, efficient, and reliable products and services to customers worldwide. To learn more, visit https://www.bitdeer.com/ or follow Bitdeer on X @ BitdeerOfficial and LinkedIn @ Bitdeer Group.

Investors and others should note that Bitdeer may announce material information using its website and/or on its accounts on social media platforms, including X, formerly known as Twitter, Facebook, and LinkedIn. Therefore, Bitdeer encourages investors and others to review the information it posts on social media and other communication channels listed on its website.

Forward–Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward–looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “look forward to,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward–looking statements, although not all forward–looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward–looking statements as a result of various important factors, including factors discussed in the section entitled “Risk Factors” in Bitdeer’s annual report on Form 20–F, as well as discussions of potential risks, uncertainties, and other important factors in Bitdeer’s subsequent filings with the U.S. Securities and Exchange Commission. Any forward–looking statements contained in this press release speak only as of the date hereof. Bitdeer specifically disclaims any obligation to update any forward–looking statement, whether due to new information, future events, or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.

Contacts:
Promotional Partnerships:
[email protected]

Sales Consultations:
[email protected]

Public Relations
BlocksBridge Consulting
Nishant Sharma
[email protected]

Investor Relations
Orange Group
Yujia Zhai
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2290e360–2026–44e3–ad19–926633309d5f


GLOBENEWSWIRE (Distribution ID 9395524)

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP–1/glucagon peptide as a once–daily tablet treatment for patients with obesity, metabolic and fibrotic disorders. The program combines OPKO’s proprietary long–acting oxyntomodulin analog (OPK–88006) and Entera’s proprietary N–Tab™ technology. Favorable pharmacodynamic, pharmacokinetic and bioavailability data in vivo were reported in September 2024. The companies expect to file an Investigational New Drug application with the U.S. Food and Drug Administration (FDA) later this year.

Under the terms of the agreement, OPKO and Entera will hold 60% and 40% pro–rata ownership interests, respectively, in the program and be responsible for 60% and 40% of the program’s development costs, respectively. In connection with the execution of the agreement, OPKO purchased 3,685,226 ordinary shares of Entera for a purchase price equal to $2.17 per share. Entera has agreed to utilize the proceeds from the sale of the shares to fund its 40% share of costs through Phase 1 of the development program. Following the completion of the Phase 1 stage, Entera has the option to continue to fund its 40% share to maintain its pro–rata ownership interest of the program. Should Entera opt–out, Entera will retain a 15% ownership interest in the Oral OXM program, while OPKO will retain 85% and be responsible for ongoing development activities and funding of the program.

“We are pleased to continue working with Entera on this promising program to develop the first oral GLP–1/Glucagon dual agonist in addition to our subcutaneous injectable dual agonist GLP–1/Glucagon program. Our goal with this franchise is to provide additional options for patients with obesity, metabolic and fibrotic diseases,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO.

“We have enjoyed our synergistic partnership with OPKO. This expanded collaboration on the GLP–1/Glucagon program reinforces our shared vision to develop first in class differentiated oral peptide treatments for patients to better manage their health,” said Miranda Toledano, Entera Chief Executive Officer.

Oxyntomodulin is a naturally occurring GLP–1/Glucagon dual agonist peptide hormone found in the small intestine that acts to suppress appetite, induce weight loss and has additional cardioprotective and anti–fibrotic attributes. OPK–88006 is a GLP–1/glucagon dual agonist peptide that has been modified to maintain its long–acting profile while increasing its potential potency. Currently, there are no approved dual GLP–1/Glucagon agonists available.

About Entera Bio

Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N–Tab™) and its pipeline includes five differentiated, first–in–class oral peptide programs targeting PTH(1–34), GLP–1 and GLP–2. The Company’s most advanced product candidate, EB613 (oral PTH(1–34)), is being developed as the first oral, osteoanabolic (bone building) once–daily tablet treatment for post–menopausal women with low BMD and high–risk osteoporosis. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is preparing to initiate a Phase 3 registrational study for EB613 pursuant to the FDA’s qualification of a quantitative BMD endpoint. The EB612 program is being developed as the first oral PTH(1–34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP–2 peptide tablet as an injection–free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, Facebook, Instagram.

About OPKO Health

OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry–leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise, and its novel and proprietary technologies. For more information, visit www.opko.com.

Cautionary Statement Regarding Forward Looking Statements
Various statements in this press release are “forward–looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release, including those regarding our prospects, plans, financial position, business strategy and expected financial and operational results, may constitute forward–looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will” and “would,” or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera’s and OPKO’s forward–looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, whether by Entera, OPKO or their respective collaboration and laboratory partners; impacts to research and development or clinical activities that Entera or OPKO may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing our product candidates; the parties’ reliance on third parties to conduct clinical trials; Entera’s and OPKO’s expectations regarding licensing, business transactions, including OPKO’s development efforts should Entera opt–out, and strategic collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s and OPKO’s intellectual property positions and their ability to protect their respective intellectual property; and other factors that are described in the “Cautionary Statements Regarding Forward–Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of each of Entera’s and OPKO’s most recent Annual Reports on Form 10–K filed with the SEC, as well as the companies’ respective subsequently filed Quarterly Reports on Form 10–Q and Current Reports on Form 8–K. There can be no assurance that the actual results or developments anticipated by Entera and OPKO will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera or OPKO, as applicable. Therefore, no assurance can be given that the outcomes stated or implied in such forward–looking statements and estimates will be achieved. Entera and OPKO caution investors not to rely on the forward–looking statements made in this press release. The information in this press release is provided only as of the date of this press release, and neither Entera nor OPKO undertakes any obligation to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.


GLOBENEWSWIRE (Distribution ID 9395480)

HKTB Launches “Four Corners of Hong Kong” Video Series Inviting Visitors to Explore the Four Points of the Compass in Hong Kong

HONG KONG, March 17, 2025 (GLOBE NEWSWIRE) — Millions of visitors choose Hong Kong as their ultimate getaway, drawn by its unique blend of breathtaking coastal scenery, lush greenery, and a dynamic cityscape just a stone’s throw away. With its long–standing commitment to green tourism, Hong Kong Tourism Board (HKTB) offers visitors enticing insights about the city’s spectacular hiking trails, outlying islands and the Geopark on its Hong Kong Great Outdoors webpage. HKTB is launching a new video series, titled “Four Corners of Hong Kong”. The series features four captivating short films that take viewers on a journey to the city’s four corners – north, south, east and west – and showcase Hong Kong's diverse scenery, with an irresistible invitation to visitors to experience the city’s extraordinary natural beauty.

The Four Points of the Compass Show Viewers Hong Kong’s Green Tourism Appeal

HKTB recently teased the campaign with an exclusive preview on Instagram, Facebook and TikTok, and releases the first full video of the four–part series today on the Discover Hong Kong YouTube channel. The remaining three episodes will come one after another throughout the coming fortnight. The video will also be released on the HKTB’s Xiaohongshu, Douyin and Weibo platforms. The videos transport viewers on an epic, fun–filled adventure in four spectacular corners of Hong Kong, climbing mountains and diving into the sea, travelling east to Sai Kung, south to Po Toi Island, Stanley, and Ap Lei Chau, west to Lantau Island, and north to Robin’s Nest Country Park. Each location has its own special charm and offers a distinct outdoor experience, demonstrating the diverse appeal and boundless potential of ecotourism in Hong Kong.

Celebrities Add a Touch of Stardust
Diverse Video Styles to Spark Visitors' Interest in Outdoor Adventures

Thai actress Eye Kamolned Ruengsri explores the newly opened Robin’s Nest Country Park in the north part of Hong Kong

Singer Wayne Huang (left) from Taiwan teams up with actor Payne Peng (right) also from Taiwan, for an island–hopping adventure on Po Toi Island in the south part of Hong Kong
Photo Credits: Young Hope Entertainment Co., LTD

HKTB has teamed up with celebrities from Thailand and Taiwan who bring a sprinkle of stardust to carry the video campaign to a wider audience. The videos, imbued with the unique charisma of the celebrities, are tailored to captivate worldwide audiences through compelling storytelling and mesmerising landscapes.

Thai actress Eye Kamolned Ruengsri, who stars in hit dramas such as Notification and the Thai version of My Love from Another Star, brings her passion for travel vlogging to the episode featuring the north of Hong Kong. Viewers follow Eye in an immersive vlog–style production as she explores the newly opened Robin’s Nest Country Park and unlocks its delights. Meanwhile, popular singer Wayne Huang from Taiwan, has teamed up with an actor from the new generation, Payne Peng, also from Taiwan, who stars in the acclaimed drama series Oh No! Here Comes Trouble, for an exciting island–hopping adventure in the episode featuring the south of Hong Kong. Combining the popular, light–hearted style of variety shows going viral in Taiwan and the duo’s witty banter and humorous interactions, the video is an entertaining and engaging watch and is sure to whet viewers’ appetite for the district’s coastal treasures.

Overview of “Four Corners of Hong Kong” Video Series

1) Experience HK100 – Asia’s Premier Trail Race: A Unique Journey Through East Hong Kong
Launch Date: 12 March 2025

East: Discovering Geological Wonders
Embark on an exhilarating race through the unforgettable landscapes of east Hong Kong, following in the footsteps of elite trail runners from the world–renowned Hong Kong 100 Ultra Marathon. The video takes viewers into the splendour of Hong Kong UNESCO Global Geopark, including Po Pin Chau and the East Dam of High Island Reservoir, and features awe–inspiring geological wonders like the rhyolitic hexagonal rock columns, which were crafted over millions of years by nature’s hand.

Along the way, viewers will also marvel at the pristine coastlines of the four bays of Tai Long Wan and Hoi Ha, which give Sai Kung its reputation as Hong Kong’s retreat haven

2) Southern Outdoors: A Day Trip to Discover Hong Kong’s Coastline
Launch Date: 21 March 2025

South: Nature at Your Fingertips
An action–packed island–hopping adventure begins! Popular singer Wayne Huang from Taiwan, and an actor from the new generation Payne Peng, also from Taiwan, set sail on an exciting exploration of Hong Kong’s southern shores. Wayne and Payne experience the thrill of kayaking off Stanley Main Beach, take selfies with the fascinating rock formations of Po Toi Island as their background, and wrap up their journey by taking a delightful kaito ferry ride to Ap Lei Chau, where they tuck into a delicious seafood feast to round off a day full of laughter and fun.

This episode celebrates a seamless blend of rugged nature and urban sophistication in Hong Kong’s Southern District where stunning coastal landscapes are just minutes from superb restaurants serving delicacies.

3) Follow Us Off the Beaten Track of West Hong Kong: LANTAU ADVENTURE
Launch Date: 18 March 2025

West: Iconic Landmarks and Natural Beauty
Sweat it out in nature’s embrace with runners from the internationally celebrated TransLantau™ by UTMB® trail race as they tackle the ultimate outdoor challenge – racing across Hong Kong’s largest island. The film captures the athletes’ ascent to Lantau Peak, Hong Kong’s second–highest mountain, and Sunset Peak, the third–highest mountain, before descending to the lush, tree–lined shores of Pui O Beach.

Pushing themselves to their physical limits, the runners follow a route that takes in must–visit attractions like the Big Buddha, Ngong Ping 360 and Tai O Fishing Village. It’s a gruelling challenge with the prize of awe–inspiring views of some of Hong Kong’s most iconic landmarks.

4) A Hike at Robin’s Nest Country Park
Launch Date: 15 March 2025

North: Uncovering Historical Treasures
Thai actress Eye Kamolned Ruengsri takes viewers on a reflective and enlightening tour of the newly opened Robin’s Nest Country Park in Hong Kong’s northernmost region. In an intimate vlog–style narrative, Eye delves into the rich history of the area, visiting sites such as the abandoned Lin Ma Hang Lead Mine, which offers a glimpse into the area’s mining past, and shows viewers remnants of World War II–era Japanese Pillboxes at Ah Kung Kok and Shan Tsui as well as the Grade 2–listed MacIntosh Forts (Kong Shan) along the boundary with the Mainland.

The film also follows Eye’s moments of relaxation as she sketches gorgeous red azaleas and majestic views of the Shenzhen Wutong Mountain Scenic Area.

Promoting the Great Outdoors Through Sport and Nature

Hong Kong’s exuberant trail running events are gaining more international interest by the year, and HKTB is stepping up its efforts to promote them to overseas visitors following the runaway success of the TransLantau™ by UTMB® and Hong Kong 100 Ultra Marathon races last year. The thrilling challenges draw athletes from the around the world and HKTB is keen to build on their unstoppable momentum. HKTB has also teamed up with industry players to offer even more outdoor adventures, such as the recently launched Hong Kong Outdoor Festival for South Korean visitors, who got the opportunity to experience Hong Kong’s urban energy and natural beauty through running. Looking ahead, HKTB will continue to invite media and influencers from key markets such as the Mainland, Southeast Asia, the UK and India to explore Hong Kong’s outdoor hotspots, inspiring more travellers to immerse themselves in the city’s extraordinary natural beauty.

Members of the media can download photos and videos from the links below:

For media inquiries, please contact:

Ms Holly Chan
Tel : 2807 6206
Email: [email protected] 		 Ms Natalie Chan
Tel : 2807 6216
Email : [email protected] 
   

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/fa5f60ad–5046–46e7–a0b5–0dd6e4aab28b

https://www.globenewswire.com/NewsRoom/AttachmentNg/bdc789cb–b609–459f–89e8–1f230fa826f3

https://www.globenewswire.com/NewsRoom/AttachmentNg/8fdd8bef–0547–4d06–98c5–295fa270ff3b


GLOBENEWSWIRE (Distribution ID 9395467)